• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.在药物研发早期发现去甲丙咪嗪羟化能力差的个体中CGP 15 210 G的药代动力学改变。
Br J Clin Pharmacol. 1985 Jul;20(1):81-4. doi: 10.1111/j.1365-2125.1985.tb02802.x.
2
The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.异喹胍氧化表型与普萘洛尔的药代动力学和药效学之间的关系。
Br J Clin Pharmacol. 1984 Jun;17(6):679-85. doi: 10.1111/j.1365-2125.1984.tb02403.x.
3
Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Clin Pharmacol Ther. 1984 Oct;36(4):515-9. doi: 10.1038/clpt.1984.212.
4
Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings.
Clin Pharmacol Ther. 1989 Jul;46(1):78-81. doi: 10.1038/clpt.1989.109.
5
The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.β-肾上腺素能受体拮抗剂的多态性氧化。临床药代动力学考量。
Clin Pharmacokinet. 1986 Jan-Feb;11(1):1-17. doi: 10.2165/00003088-198611010-00001.
6
Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation.可待因O-去甲基化与多态性异喹胍羟基化共分离。
Br J Clin Pharmacol. 1989 Dec;28(6):639-45. doi: 10.1111/j.1365-2125.1989.tb03556.x.
7
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.在异喹胍羟化能力差的个体中，美托洛尔代谢存在缺陷。
Br J Clin Pharmacol. 1982 Aug;14(2):301-3. doi: 10.1111/j.1365-2125.1982.tb01982.x.
8
E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation.去甲替林的E型和Z型10-羟基化作用：与异喹胍多态性羟基化作用的关系。
Clin Pharmacol Ther. 1981 Aug;30(2):189-93. doi: 10.1038/clpt.1981.147.
9
Polymorphism of debrisoquine hydroxylation among Finns and Lapps.芬兰人和拉普人中异喹胍羟基化的多态性。
Br J Clin Pharmacol. 1988 Nov;26(5):601-3. doi: 10.1111/j.1365-2125.1988.tb05301.x.
10
The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine.
Eur J Clin Pharmacol. 1987;33(1):59-65. doi: 10.1007/BF00610381.

引用本文的文献

1
Role of cytochrome P4502D6 in the metabolism of brofaromine. A new selective MAO-A inhibitor.细胞色素P4502D6在溴法罗明（一种新型选择性单胺氧化酶-A抑制剂）代谢中的作用。
Eur J Clin Pharmacol. 1993;45(3):265-9. doi: 10.1007/BF00315394.
2
Clinical significance of the sparteine/debrisoquine oxidation polymorphism.司巴丁/异喹胍氧化多态性的临床意义
Eur J Clin Pharmacol. 1989;36(6):537-47. doi: 10.1007/BF00637732.
3
Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.肝脏药物氧化的最新进展。对临床药代动力学的影响。
Clin Pharmacokinet. 1990 Mar;18(3):220-39. doi: 10.2165/00003088-199018030-00004.

本文引用的文献

1
A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.对英国白人人群中异喹胍氧化遗传多态性的家系及群体研究。
J Med Genet. 1980 Apr;17(2):102-5. doi: 10.1136/jmg.17.2.102.
2
[Drug hydroxylation disorders (debrisoquin type) in a random sample of the Swiss population].
Schweiz Med Wochenschr. 1982 Jul 24;112(30):1061-7.
3
Protecting poor metabolizers, a group at high risk of adverse drug reactions.保护代谢缓慢者，这是一组药物不良反应高风险人群。
Lancet. 1983 Jun 18;1(8338):1388. doi: 10.1016/s0140-6736(83)92172-4.
4
Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionization and nitrogen-selective detection.采用气相色谱-火焰离子化和氮选择性检测法测定生物流体中的异喹胍及其4-羟基代谢物。
J Chromatogr. 1977 Mar 11;133(1):161-6. doi: 10.1016/s0021-9673(00)89216-x.
5
Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.药物碳中心氧化的多态性及其临床意义。
Drug Metab Rev. 1979;9(2):301-17. doi: 10.3109/03602537908993896.
6
Polymorphic hydroxylation of Debrisoquine in man.人对异喹胍的多态性羟基化作用。
Lancet. 1977 Sep 17;2(8038):584-6. doi: 10.1016/s0140-6736(77)91430-1.

在药物研发早期发现去甲丙咪嗪羟化能力差的个体中CGP 15 210 G的药代动力学改变。

Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development.

作者信息

Gleiter C H, Aichele G, Nilsson E, Hengen N, Antonin K H, Bieck P R

出版信息

Br J Clin Pharmacol. 1985 Jul;20(1):81-4. doi: 10.1111/j.1365-2125.1985.tb02802.x.

DOI:10.1111/j.1365-2125.1985.tb02802.x
PMID:4027140
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1400618/
Abstract

The pharmacokinetics of CGP 15 210 G, a new 5-HT uptake inhibitor in poor and extensive metabolisers of debrisoquine, give indirect evidence of an association between its metabolism and polymorphic hydroxylation of the debrisoquine type.

摘要

CGP 15 210 G是一种新型5-羟色胺摄取抑制剂，在异喹胍代谢能力差和代谢能力强的人群中的药代动力学，间接证明了其代谢与异喹胍型多态性羟基化之间存在关联。